Fiscal Receipts

Senate LDA lobbying filing

Pfizer Inc.

A public disclosure record: who filed, what they reported, and the program connections found in the text.
Reported amountsProgram mentionsActivity textLobbyists
Registrant: Pfizer Inc. Year: 2025 Period: First Quarter Type: Q1

Filed as: PFIZER INC.. Search lda.senate.gov for that string; the name above is this site’s casing of it, nothing else.

View on lda.senate.gov ↗

Reported income

not reported

Reported expenses

$4.24M

Connections in the record

Tracked program mentions1

Quoted activity text is clipped to a short extract; each filing’s full description is under Lobbying activities below.

Lobbying activities5

  • Budget/AppropriationsBUD

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 Budget Reconciliation

  • Health IssuesHCR

    S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - EPIC Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act S 1040 - Drug Competition Enhancement Act HR 946 - ORPHAN Cures Act HR 1492 - EPIC Act Biosimilars Access & Reimbursement 340B Reform 340B Access Act Inflation Reduction Act (IRA) Biosimilar Pause Inflation Reduction Act (IRA) Pill Penalty Vaccine Coverage Intellectual Property Protections PBM Reform Lower Cost More Transparency Act Bayh-Dole Act March-In Rights Cancer Policies Drug Pricing/Foreign Reference Pricing Digital Therapeutics Access & Reimbursement Patient Out of Pocket Costs

  • Medicare/MedicaidMMM

    S 526 - Pharmacy Benefit Manager Transparency Act of 2025 S 527 - Prescription Pricing for the People Act of 2025 S 832 - Epic Act of 2025 S 864 - HELP Copays Act S 882 - Patients Before Middlemen Act HR 946 - ORPHAN Cures Act PBM Reform Medicaid Prescription Drug Access

  • Taxation/Internal Revenue CodeTAX

    H. Con. Res. 14 - Establishing the congressional budget for the US Government for FY 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034 VICP Reform and Excise Tax Tax Cuts and Jobs Act (TCJA) Comprehensive Corporate Tax Reform

  • Trade (domestic/foreign)TRD

    HR 2213 - Authorize the President to Enter Into Trade Agreements for the Reciprocal Elimination of Duties or Other Import Restrictions with Respect to Medical Goods Medical Supply Chain Resiliency Act International Supply Chain Tariffs Non-Tariff Trade Barriers

Lobbyists8

  • ANGELA WILES
  • CATHERINE ROBINSON
  • ELISSA ALBEN
  • EMILY MUELLER
  • JENNIFER WALTON
  • MATTHEW STROIA
  • PAULA BURG
  • STEPHEN CLAEYS

Source: U.S. Senate Lobbying Disclosure Act database. Underlined dollar figures cite the filing record on lda.senate.gov and open to that citation. Amounts shown as “not reported” are absent from the filing itself.